3637

Brown MS, Goldstein JL. Biomedicine. Lowering LDL – not only how low, but how long? Science. 2006;311(5768):1721–3. https://pubmed.ncbi.nlm.nih.gov/16556829/

3638

Kahleova H, Levin S, Barnard ND. Vegetarian dietary patterns and cardiovascular disease. Prog Cardiovasc Dis. 2018;61(1):54–61. https://pubmed.ncbi.nlm.nih.gov/29800598/

3639

O’Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11):2142–6. https://pubmed.ncbi.nlm.nih.gov/15172426/

3640

Roberts WC. Cholesterol is the cause of atherosclerosis. Am J Cardiol. 2017;120(9):1696. https://pubmed.ncbi.nlm.nih.gov/28847597/

3641

Kataoka Y, Hammadah M, Puri R, et al. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis. 2015;242(2):490–5. https://pubmed.ncbi.nlm.nih.gov/26298740/

3642

Diamond DM, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Rev Clin Pharmacol. 2015;8(2):201–10. https://pubmed.ncbi.nlm.nih.gov/25672965/

3643

Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patients’ expectation of benefit from preventive drugs. Clin Med (Lond). 2002;2(6):527–33. https://pubmed.ncbi.nlm.nih.gov/12528966/

3644

Salami JA, Warraich H, Valero-Elizondo J, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2(1):56–65. https://pubmed.ncbi.nlm.nih.gov/29358195/

3645

Diprose W, Verster F. The preventive-pill paradox: how shared decision making could increase cardiovascular morbidity and mortality. Circulation. 2016;134(21):1599–600. https://pubmed.ncbi.nlm.nih.gov/27881503/

3646

Ziaeian B, Fonarow GC. Statins and the prevention of heart disease. JAMA Cardiol. 2017;2(4):464. https://pubmed.ncbi.nlm.nih.gov/28122083/

3647

ASCVD Risk Estimator Plus. American College of Cardiology. https://tools.acc.org/ASCVD-Risk-Estimator/. Accessed April 3, 2022.; https://tools.acc.org/ASCVD-Risk-Estimator/

3648

Framingham Risk Score. Medscape. https://reference.medscape.com/calculator/framingham-cardiovascular-disease-risk. Accessed April 3, 2022.; https://reference.medscape.com/calculator/252/framingham-risk-score-2008

3649

Reynolds Risk Score. https://www.reynoldsriskscore.org. Accessed April 3, 2022.; https://www.reynoldsriskscore.org/

3650

Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73(24):3153–67. https://pubmed.ncbi.nlm.nih.gov/30586766/

3651

Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73(24):3153–67. https://pubmed.ncbi.nlm.nih.gov/30586766/

3652

Curry SJ, Krist AH, Owens DK, et al. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(3):272–80. https://pubmed.ncbi.nlm.nih.gov/29998297/

3653

Diamond DM, de Lorgeril M, Kendrick M, Ravnskov U, Rosch PJ. Formal comment on “Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease.” PLoS One. 2019;14(1):e0205138. https://pubmed.ncbi.nlm.nih.gov/30653537/

3654

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83. https://pubmed.ncbi.nlm.nih.gov/24079289/

3655

Ward NC, Watts GF, Eckel RH. Statin toxicity: mechanistic insights and clinical implications. Circ Res. 2019;124(2):328–50. https://pubmed.ncbi.nlm.nih.gov/30653440/

3656

Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as treatment for statin-associated muscle symptoms – a good idea, but…. Adv Nutr. 2018;9(4):519S-23S. https://pubmed.ncbi.nlm.nih.gov/30032220/

3657

Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24–34. https://pubmed.ncbi.nlm.nih.gov/25440725/

3658

Armour R, Zhou L. Outcomes of statin myopathy after statin withdrawal. J Clin Neuromuscul Dis. 2013;14(3):103–9. https://pubmed.ncbi.nlm.nih.gov/23492461/

3659

Majeed A, Molokhia M. Urgent need to establish the true incidence of the side effects of statins. BMJ. 2014;348:g3650. https://pubmed.ncbi.nlm.nih.gov/24920685/

3660

Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74. https://pubmed.ncbi.nlm.nih.gov/24623264/

3661

Climent E, Benaiges D, Pedro-Botet J. Statin treatment and increased diabetes risk. Possible mechanisms. Clínica e Investigación en Arteriosclerosis. 2019;31(5):228–32. https://pubmed.ncbi.nlm.nih.gov/30737072/

3662

Mansi IA, English J, Zhang S, Mortensen EM, Halm EA. Long-term outcomes of short-term statin use in healthy adults: a retrospective cohort study. Drug Saf. 2016;39(6):543–59. https://pubmed.ncbi.nlm.nih.gov/26979831/

3663

The Panel on Food Additives and Nutrient Sources, Aggett P, Aguilar F, et al. Scientific opinion on the safety of monacolins in red yeast rice. EFSA J. 2018;16(80):5368. https://pubmed.ncbi.nlm.nih.gov/32626016/

3664

Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722–7. https://pubmed.ncbi.nlm.nih.gov/20975018/

3665

Righetti L, Dall’Asta C, Bruni R. Risk assessment of RYR food supplements: perception vs. reality. Front Nutr. 2021;8:792529. https://pubmed.ncbi.nlm.nih.gov/34950692/

3666

Murphy SL, Kochanek KD, Xu J, Arias E. Mortality in the United States, 2020. NCHS Data Brief, No. 427. https://www.cdc.gov/nchs/products/databriefs/db427.htm. Published December 2021. Accessed January 3, 2023.; https://www.cdc.gov/nchs/products/databriefs/db427.htm

3667

Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(10):875–81. https://pubmed.ncbi.nlm.nih.gov/22902202/

3668

Newman CB, Preiss D, Tobert JA, et al. Statin